Emerging treatments like rusfertide may reduce phlebotomies and improve life for patients with polycythemia vera, according ...

Ionis Pharmaceuticals (IONS) shares ended the last trading session 9.1% higher at $43.59. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Fintel reports that on July 1, 2025, Barclays upgraded their outlook for Ionis Pharmaceuticals (NasdaqGS:IONS) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 47.25% Upside As of ...

Ionis ended Q1 with $2.1 billion in cash, cash equivalents, and short-term investments. The company’s long-term debt is made up of convertible senior notes and totals approximately $1.4 billion.

Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera Published on June 24, 2025 at 3:09 pm by Maham Fatima in News ...

Polycythemia vera results from an acquired genetic mutation rather than an inherited one. Learn more.

The Vera C. Rubin Observatory has just released some of its first images. Its powerful new telescope will be able to quickly spot previously unseen astronomical objects.

The Vera C. Rubin Observatory has released its first images, providing a staggering glimpse at the observing power it will unleash when it begins its decade-long survey.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice ...

The Vera C. Rubin Observatory will make the study of stars and galaxies more like the big data-sorting exercises of contemporary genetics and particle physics.